➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKinsey
Boehringer Ingelheim
Colorcon
Harvard Business School

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Masitinib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Masitinib?

Masitinib is an investigational drug.

There have been 31 clinical trials for Masitinib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2011.

The most common disease conditions in clinical trials are Gastrointestinal Stromal Tumors, Mastocytosis, and Sclerosis. The leading clinical trial sponsors are AB Science and [disabled in preview].

There are sixteen US patents protecting this investigational drug and one hundred and eighty-nine international patents.

Recent Clinical Trials for Masitinib
TitleSponsorPhase
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentAB SciencePhase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsAB SciencePhase 3
Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil LevelsAB SciencePhase 3

See all Masitinib clinical trials

Clinical Trial Summary for Masitinib

Top disease conditions for Masitinib
Top clinical trial sponsors for Masitinib

See all Masitinib clinical trials

US Patents for Masitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Masitinib   Start Trial Fusion proteins and methods thereof The Trustees of Columbia University in the City of New York (New York, NY)   Start Trial
Masitinib   Start Trial Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors AB SCIENCE (Paris, FR)   Start Trial
Masitinib   Start Trial 2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases AB Science (Paris, FR)   Start Trial
Masitinib   Start Trial Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors AB Science (Paris, FR)   Start Trial
Masitinib   Start Trial Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors AB Science (Paris, FR)   Start Trial
Masitinib   Start Trial Anti-IGF antibodies Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Masitinib   Start Trial 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB Science (Paris, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Masitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Masitinib Australia 2014236947 2033-03-15   Start Trial
Masitinib Canada 2907152 2033-03-15   Start Trial
Masitinib European Patent Office 2968551 2033-03-15   Start Trial
Masitinib Japan 2016515508 2033-03-15   Start Trial
Masitinib South Korea 20150129847 2033-03-15   Start Trial
Masitinib World Intellectual Property Organization (WIPO) 2014151734 2033-03-15   Start Trial
Masitinib Argentina 092899 2032-10-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKinsey
Medtronic
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.